BRADBURY DANIEL 4

What Happened

• Daniel Bradbury, Chairman and director of Equillium, was granted a derivative award covering 70,000 shares on May 28, 2026. The reported acquisition price is $0.00, and the filing classifies this as an award/grant (derivative), not an open-market purchase or sale. This is a grant of compensation/incentive equity rather than a cash purchase or sale.

Key Details

• Transaction date: 2026-05-28; Form 4 filed: 2026-05-29 (timely).
• Transaction type: Grant / award (derivative) for 70,000 shares, reported price $0.00.
• Shares owned after transaction: Not specified in the filing.
• Footnote: The option vests in 12 equal monthly installments beginning May 28, 2026, but will be fully vested by the issuer's next annual meeting of stockholders following the grant date.
• Filing timeliness: Not indicated as late.

Context

• This was a grant of derivative award (likely an option or similar equity incentive); no exercise or sale occurred and no cash changed hands per the reported $0.00 price. Grants like this are commonly part of executive compensation and do not by themselves indicate an immediate buying or selling signal.